nuvalore Joins APV 2026 Programme Committee for Drug-Device Combination Products Workshop

Leimen, Germany — nuvalore GmbH will participate in the 2nd APV Workshop on Drug-Device Combination Products for Parenteral Use, taking place in Basel, Switzerland.

As drug-device combination products continue to evolve, the industry is facing increasing complexity across formulation development, device integration, analytical characterization, regulatory expectations, and patient-centric delivery systems.

Organized by APV – International Association for Pharmaceutical Technology, the workshop brings together experts from across parenteral formulations, biologics, vaccines, and advanced therapeutic systems to discuss emerging challenges in combination product development.

Key topics this year include:

• Autoinjectors, prefilled syringes & wearable injection devices
• High-dose and high-concentration formulations
• Digitally connected systems
• Regulatory strategy & bioavailability
• Sustainability and lifecycle considerations

nuvalore will sponsor the event, and Founder & CEO Dr. Anamarija Ćurić is part of the programme committee helping shape this year’s scientific agenda alongside experts from across pharma, biologics, medical devices, and regulatory sciences.

nuvalore is a GMP-certified contract quality control laboratory that supports pharmaceutical and biotechnology companies developing combination products through analytical and scientific expertise, helping address challenges related to product characterization, device compatibility, regulatory requirements, and commercialization readiness.

Whether you plan to meet on-site in Basel or connect virtually, you can schedule a meeting with Dr. Ćurić, to discuss combination product development and analytical challenges.

See event details and registration information below:

📅 09–10 June 2026

📍 Basel, Switzerland

👉 View full agenda & register here

About nuvalore GmbH

nuvalore GmbH is a GMP-certified contract quality control laboratory based in Leimen, Baden-Württemberg, specializing in the analytical characterization of pharmaceuticals and biopharmaceuticals.

Founded in 2024, nuvalore supports clients with analytical method development, validation, and transfer, as well as Quality by Design (QbD)-driven approaches using Design of Experiments (DoE). Its capabilities include pharmacopoeial quality control, protein and surfactant analysis, ELISA, nanoparticle characterization, and testing of primary packaging and drug delivery systems.

Operating under a quality management system aligned with EU GMP and ICH guidelines, nuvalore provides pharmaceutical and biotechnology companies with reliable, regulatory-ready analytical data.

To learn more, visit:  https://nuvalore.com/en/

Resources

Schedule a meeting with Dr. Anamarija Ćurić to discuss combination product development and analytical challenges.
Explore nuvalore services brochure.